Survival and Treatment of Lung Cancer in Taiwan Between 2010 and 2016

Overview

Journal J Clin Med

Specialty General Medicine

Date 2021 Oct 23

PMID 34682798

Citations 13

Authors

Yen-Jung Chang

Jing-Yang Huang

Ching-Hsiung Lin

Bing-Yen Wang

Affiliations

Soon will be listed here.

Abstract

Background: Lung cancer is the leading cause of cancer-related death, and its incidence is still growing in Taiwan. This study investigated the prognostic factors of overall survival between 2010 and 2016 in Taiwan.

Methods: Data from 2010 to 2016 was collected from the Taiwan Cancer Registry (TCR). The characteristics and overall survival of 71,334 lung cancer patients were analyzed according to the tumor, node, metastasis (TNM) 7th staging system. Univariate and multivariate analysis were performed to identify the prognostic factors.

Results: The five-year overall survival ( = 71,334) was 25.0%, and the median survival was 25.3 months. The five-year overall survival of patients receiving any kind of treatment ( = 65,436; 91.7%) and surgical resection ( = 20,131; 28.2%) was 27.09% and 69.93%, respectively. The clinical staging distribution was as follows: stage IA (9208, 12.9%), stage IB (4087, 5.7%), stage IIA (1702, 2.4%), stage IIB (1454, 2.0%), stage IIIA (5309, 7.4%), stage IIIB (6316, 8.9%), stage IV (41458, 58.1%). Age, sex, Charlson comorbidity index, cell type, clinical T, clinical N, clinical M, grading and treatment strategy are independent prognostic factors in the multivariate analysis.

Conclusion: The outcome for lung cancer patients was still poor. The identification of prognostic factors could facilitate in choosing treatment strategies and designing further randomized clinical trials.

Citing Articles

Unmet Supportive Care Needs of Lung Cancer Survival Patients at Different Cancer Stages and Treatment Phases.

Lee P, Chen Y, Tsai T, Chen C, Shieh S J Multidiscip Healthc. 2025; 18:435-444.

PMID: 39896726 PMC: 11784348. DOI: 10.2147/JMDH.S482232.

Trimodal therapy and surgical approaches in stage IIIA/N2 non-small cell lung cancer.

Hu P, Huang J, Cheng Y, Cheng C, Huang C, Hung W Sci Rep. 2024; 14(1):29441.

PMID: 39604439 PMC: 11603048. DOI: 10.1038/s41598-024-79158-9.

Importance of driver gene mutation assessment and targeted therapy for patients with early‑stage non‑small cell lung cancer and non‑R0 resection.

Shen P, Chuang C, Lin C, Hsu Y, Huang Y, Hsu K Oncol Lett. 2024; 29(1):35.

PMID: 39512503 PMC: 11542149. DOI: 10.3892/ol.2024.14780.

Predicting Lung Cancer Survival to the Future: Population-Based Cancer Survival Modeling Study.

Meng F, Jhuang J, Peng Y, Chiang C, Yang Y, Huang C JMIR Public Health Surveill. 2024; 10():e46737.

PMID: 38819904 PMC: 11179019. DOI: 10.2196/46737.

Evaluation of the effects of postoperative pleural empyema on survival rates of patients after pneumonectomy due to non-small cell lung cancer.

Wojcik J, Grodzki T, Safranow K, Pierog J, Wojtys M, Kordykiewicz D Kardiochir Torakochirurgia Pol. 2024; 21(1):1-7.

PMID: 38693979 PMC: 11059016. DOI: 10.5114/kitp.2024.138376.

References

Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

Gunn J, Valo J, Sipila J, Rautava P, Sihvo E, Kyto V . Trends and results of lung cancer surgery in Finland between 2004 and 2014. Eur J Cardiothorac Surg. 2018; 54(1):127-133. DOI: 10.1093/ejcts/ezx486. View

Vallieres E, Shepherd F, Crowley J, Van Houtte P, Postmus P, Carney D . The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2009; 4(9):1049-59. DOI: 10.1097/JTO.0b013e3181b27799. View

Wang B, Huang J, Chen H, Lin C, Lin S, Hung W . The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients. J Cancer Res Clin Oncol. 2019; 146(1):43-52. DOI: 10.1007/s00432-019-03079-8. View

Riaz S, Linklater K, Page R, Peake M, Moller H, Luchtenborg M . Recent trends in resection rates among non-small cell lung cancer patients in England. Thorax. 2012; 67(9):811-4. DOI: 10.1136/thoraxjnl-2012-201768. View

de Koning H, van der Aalst C, de Jong P, Scholten E, Nackaerts K, Heuvelmans M . Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020; 382(6):503-513. DOI: 10.1056/NEJMoa1911793. View

Yoshizawa A, Motoi N, Riely G, Sima C, Gerald W, Kris M . Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011; 24(5):653-64. DOI: 10.1038/modpathol.2010.232. View

Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M . Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391(10125):1023-1075. PMC: 5879496. DOI: 10.1016/S0140-6736(17)33326-3. View

Tang E, Schreiner A, Pua B . Advances in lung adenocarcinoma classification: a summary of the new international multidisciplinary classification system (IASLC/ATS/ERS). J Thorac Dis. 2014; 6(Suppl 5):S489-501. PMC: 4209385. DOI: 10.3978/j.issn.2072-1439.2014.09.12. View

10.

Wang B, Huang J, Cheng C, Lin C, Ko J, Liaw Y . Lung cancer and prognosis in taiwan: a population-based cancer registry. J Thorac Oncol. 2013; 8(9):1128-35. DOI: 10.1097/JTO.0b013e31829ceba4. View

11.

Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt W . The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016; 11(1):39-51. DOI: 10.1016/j.jtho.2015.09.009. View

12.

Schabath M, Cote M . Cancer Progress and Priorities: Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2019; 28(10):1563-1579. PMC: 6777859. DOI: 10.1158/1055-9965.EPI-19-0221. View

13.

Butnor K . Controversies and challenges in the histologic subtyping of lung adenocarcinoma. Transl Lung Cancer Res. 2020; 9(3):839-846. PMC: 7354137. DOI: 10.21037/tlcr.2019.12.30. View

14.

Cheng T, Cramb S, Baade P, Youlden D, Nwogu C, Reid M . The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics. J Thorac Oncol. 2016; 11(10):1653-71. PMC: 5512876. DOI: 10.1016/j.jtho.2016.05.021. View

15.

Gadgeel S, Ramalingam S, Cummings G, Kraut M, Wozniak A, Gaspar L . Lung cancer in patients < 50 years of age: the experience of an academic multidisciplinary program. Chest. 1999; 115(5):1232-6. DOI: 10.1378/chest.115.5.1232. View

16.

Chansky K, Sculier J, Crowley J, Giroux D, Meerbeeck J, Goldstraw P . The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 2009; 4(7):792-801. DOI: 10.1097/JTO.0b013e3181a7716e. View

17.

Narsule C, Ebright M, Fernando H . Sublobar versus lobar resection: current status. Cancer J. 2011; 17(1):23-7. DOI: 10.1097/PPO.0b013e31820a51b6. View

18.

Forde P, Kelly R, Brahmer J . New strategies in lung cancer: translating immunotherapy into clinical practice. Clin Cancer Res. 2014; 20(5):1067-73. DOI: 10.1158/1078-0432.CCR-13-0731. View

19.

Altorki N, Kohman L, Veit L, You Y, Boughey J . Limited resection as a cure for early lung cancer: time to challenge the gold standard?. Bull Am Coll Surg. 2015; 100(5):57-8. View

20.

Nakamura K, Saji H, Nakajima R, Okada M, Asamura H, Shibata T . A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). Jpn J Clin Oncol. 2009; 40(3):271-4. DOI: 10.1093/jjco/hyp156. View